- Unique patented drug delivery platform
- Active in world’s largest beverage market
- Technology that compliments rather than competes with CBD companies
An old and popular beverage is being supplemented in a healthy, flavorful way now that Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is on the scene. Having increased its ownership stake in PoViva Tea, LLC from 51% to 100%, the innovative drug delivery biotech plans to apply its patented DehydraTECH™ technology to supplement a range of black teas with cannabidiol (CBD) from hemp. After water, tea is the most widely consumed beverage in the world and is an ideal adjuvant to speed adoption of CBD supplements. Now that it is complementing the recognized virtues of tea with the therapeutic benefits of CBD, Lexaria is poised to revolutionize the age-old ritual of afternoon tea.
America is a nation of tea drinkers. In 2016, Americans drank 84 billion cups of tea; that is 260 cups for every man, woman and child. Of the 3.8 billion gallons thus consumed, about 80% was black tea, 16% was green tea, while the rest was either Oolong, white or dark tea. Unlike the rest of the world, Americans like their tea cold. About 80 percent of the tea consumed on a daily basis is chilled. However, hot tea appears to be gaining in popularity with the health conscious. The Tea Association of the USA reports (http://cnw.fm/m7X6J) that ‘total category sales for hot tea have increased more than 15% over the last 5 years…’ The Association ‘anticipates strong, continuous growth, with a CAGR of 4-6% (coming) from all segments driven by variety, convenience, health benefits, sustainability, availability, continued innovation and the discovery of unique, flavorful and high-end specialty teas’.
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer